Patent intelligence · US
US 12390462
Muscarinic acetylcholine M1 receptor antagonists
Muscarinic acetylcholine M1 receptor antagonists
Patent details — US 12390462
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 19, 2025
- Expiration
- Aug 14, 2045
- Applicant
- Contineum Therapeutics, Inc.
- Claims
- 6
- CPC classes
- A61K, A61K31/4995, A61K31/501, A61K45/06
Quick answer
US 12390462 (Muscarinic acetylcholine M1 receptor antagonists) is held by Contineum Therapeutics, Inc.. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Contineum Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/4995, A61K31/501, A61K45/06
More from Contineum Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12390462?
US 12390462 (Muscarinic acetylcholine M1 receptor antagonists) is held by Contineum Therapeutics, Inc.. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12390462?
Contineum Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12390462 expire?
Our index shows an expiration date of Aug 14, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.